Ligufalimab (AK 117): A Comprehensive Profile of a Differentiated, Next-Generation CD47 Inhibitor

Executive Summary

Ligufalimab, also known as AK 117, is an investigational, humanized immunoglobulin G4 (IgG4) monoclonal antibody developed by Akeso Inc. that targets the CD47-SIRPα innate immune checkpoint.[1] This report provides a comprehensive analysis of Ligufalimab, synthesizing available preclinical, clinical, and strategic data to assess its potential as a therapeutic agent in oncology. The central value proposition of Ligufalimab lies in its differentiated safety profile, which has been engineered to mitigate the class-defining hematotoxicity—specifically hemagglutination and severe anemia—that has challenged first-generation CD47 inhibitors.[4] This favorable safety profile, which obviates the need for a risk-mitigating "priming dose," positions Ligufalimab as a potential best-in-class agent.

Akeso is pursuing a sophisticated and ambitious clinical development strategy for Ligufalimab, characterized by its focus on creating proprietary, high-efficacy combination regimens with its other advanced pipeline assets. These include the PD-1/VEGF bispecific antibody Ivonescimab and the PD-1/CTLA-4 bispecific antibody Cadonilimab.[7] This approach aims to create a multi-pronged attack on the tumor microenvironment by simultaneously engaging both innate and adaptive immunity.

The clinical program for Ligufalimab is broad, spanning both hematologic malignancies and a wide array of solid tumors. In hematology, it is being investigated in combination with standard-of-care agents for higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML).[3] In solid tumors, Ligufalimab is advancing into late-stage, global, registrational trials, most notably a landmark Phase 3 study in combination with Ivonescimab versus pembrolizumab for the first-line treatment of head and neck squamous cell carcinoma (HNSCC).[8]

Emerging clinical data have been promising, demonstrating high response rates in HR-MDS and validating the superior safety profile in human subjects.[11] By learning from the challenges of its predecessors and engineering a solution to the class's primary liability, Akeso has positioned Ligufalimab not as a mere "me-too" drug, but as a strategic "fast follower" with the potential to become a best-in-class therapy. Its success will depend on the outcomes of its pivotal trials and its ability to demonstrate a superior net clinical benefit in multiple oncology settings.

Drug Profile and Scientific Foundation

This section establishes the fundamental scientific rationale for Ligufalimab, focusing on its mechanism of action and the key structural and functional features that underpin its primary competitive advantage in the field of CD47-targeted immunotherapy.

Identification and Physicochemical Properties

Ligufalimab is a protein-based therapeutic agent classified as a humanized monoclonal antibody. It has been developed and is being investigated by Akeso Inc. under the internal research code AK 117.[1] The drug's structural and identifying characteristics are consolidated in the table below.

Identifier	Details	Source(s)
Generic Name	Ligufalimab	1
Synonyms/Code Names	AK 117, AK-117, AK117	1
DrugBank ID	DB17542	1
CAS Number	2428381-55-7	2
Drug Type	Biotech, Protein-Based Therapy	1
Molecular Class	Humanized Immunoglobulin G4 (IgG4) kappa, Monoclonal Antibody	1
Molecular Weight	Approximately 144.58 kDa	15
Source	Chinese Hamster Ovary (CHO) cells	15
Target	Leukocyte surface antigen CD47 (Integrin-Associated Protein)	1

Mechanism of Action: Targeting the CD47-SIRPα Immune Checkpoint

The therapeutic strategy of Ligufalimab is centered on the inhibition of the CD47-signal regulatory protein alpha (SIRPα) signaling pathway, a critical innate immune checkpoint.[6] CD47 is a transmembrane glycoprotein widely expressed on the surface of nearly all healthy human cells. Its primary physiological function is to act as a marker of "self" by binding to the SIRPα receptor present on myeloid cells, particularly macrophages and dendritic cells.[19] This interaction delivers a potent inhibitory signal—colloquially known as a "don't eat me" signal—that actively suppresses phagocytosis, thereby preventing the immune system from destroying healthy host cells.[6]

Many types of cancer cells have been found to exploit this natural self-preservation mechanism to evade immune surveillance. They achieve this by overexpressing CD47 on their cell surface, which effectively masks them from the innate immune system.[19] This overexpression has been correlated with poor prognosis across a variety of hematologic malignancies and solid tumors.[6]

Ligufalimab functions as an immune checkpoint inhibitor by targeting and binding to CD47 expressed on tumor cells.[18] This binding physically obstructs the interaction between CD47 and SIRPα.[6] By abrogating this inhibitory "don't eat me" signal, Ligufalimab effectively "unmasks" the cancer cells, making them vulnerable to destruction by phagocytic cells.[3] This process enables pro-phagocytic signals, such as the exposure of calreticulin on the tumor cell surface, to dominate, leading to macrophage activation and subsequent engulfment of the malignant cells.[18] Beyond its direct effect on innate immunity, this blockade also facilitates the activation of the adaptive immune system. Macrophages that have engulfed tumor cells can process and present tumor-associated antigens to T-lymphocytes, priming a specific and durable anti-tumor T-cell response.[20]

The Key Differentiator: A Novel Binding Epitope and Avoidance of Hemagglutination

The development of first-generation CD47-targeting therapies has been significantly hampered by a class-defining safety liability: on-target, off-tumor hematotoxicity.[5] Because CD47 is ubiquitously expressed on healthy hematopoietic cells, particularly red blood cells (RBCs), early anti-CD47 antibodies induced significant hemagglutination (clumping of RBCs) and anemia.[5] This toxicity often necessitated complex risk mitigation strategies, such as the administration of a low initial "priming dose" to saturate CD47 on RBCs before escalating to a therapeutic dose, which complicates treatment and can limit efficacy.[11]

The development of Ligufalimab represents a strategic effort to overcome this fundamental challenge. Akeso employed a deliberate, safety-first design approach, utilizing a discovery and screening process that was specifically engineered to identify an antibody candidate that did not induce hemagglutination.[6] This effort yielded a molecule with a distinct and advantageous safety profile rooted in its unique structural interaction with its target.

Preclinical structural analysis and in silico modeling suggest that Ligufalimab binds to a novel epitope on the CD47 protein.[20] This binding results in a specific conformation where the two antigen-binding fragments (Fab) of the bivalent IgG4 antibody engage two CD47 molecules that are oriented nearly parallel to each other. This spatial arrangement makes it sterically unlikely for a single Ligufalimab antibody to simultaneously bind to CD47 proteins on two different RBCs.[6] In contrast, the binding mode of the first-generation antibody Hu5F9-G4 (magrolimab) results in a wider, Y-shaped conformation that is more permissive for cross-linking cells, which is the direct physical cause of agglutination.[6]

The functional consequences of this engineered design are profound. In vitro studies have confirmed that Ligufalimab does not induce RBC hemagglutination, even at concentrations up to 3000 nM, whereas Hu5F9-G4 induces agglutination at concentrations as low as 4.1 nM.[17] Furthermore, Ligufalimab exhibits significantly weaker binding to erythrocytes and induces a markedly lower degree of erythrophagocytosis (phagocytosis of RBCs) compared to Hu5F9-G4.[6] This superior safety profile is not an incidental finding but the core pillar of Ligufalimab's value proposition. It allows for simpler and potentially more effective dosing regimens, reduces the risk of severe on-target toxicities, and makes it a more attractive partner for combination therapies where minimizing overlapping toxicities is paramount.

Preclinical Evidence of Anti-Tumor Activity and Safety

Preclinical studies have robustly demonstrated that Ligufalimab's enhanced safety profile does not compromise its anti-tumor efficacy.

Binding Affinity and Target Engagement: Surface plasmon resonance and ELISA assays have shown that Ligufalimab binds to human CD47 with high affinity, with a dissociation constant (KD​) of approximately 0.152 nM.[5] It potently blocks the CD47-SIRPα interaction, with activity comparable to that of the benchmark competitor, Hu5F9-G4.[4]

In Vitro Efficacy: In functional assays, Ligufalimab induced potent, dose-dependent phagocytosis of various human hematologic cancer cell lines, including Raji, Jurkat, and Ramos cells.[2] Its activity was further enhanced when used in combination with opsonizing antibodies. For example, co-administration with rituximab (an anti-CD20 antibody) or cetuximab (an anti-EGFR antibody) significantly increased the phagocytosis of lymphoma and colorectal cancer cells, respectively, demonstrating its potential for synergistic activity with other targeted therapies.[6]

In Vivo Efficacy: In mouse xenograft models, Ligufalimab demonstrated robust single-agent anti-tumor activity. In a Raji B-cell lymphoma model, doses of 0.1 mg/kg and 1 mg/kg resulted in tumor growth inhibition of 63.78% and 88.56%, respectively.[17] In a triple-negative breast cancer model (MDA-MB-231), Ligufalimab showed efficacy comparable to or, at lower doses, significantly higher than Hu5F9-G4.[4] The potential for combination therapy was further highlighted in a humanized mouse model, where the combination of Ligufalimab with Akeso's anti-PD-1/VEGF bispecific antibody, AK112 (Ivonescimab), resulted in a dramatic and statistically significant inhibition of tumor growth, far exceeding the effect of either agent alone.[4]

Non-Human Primate (NHP) Safety: Crucially, the favorable safety profile was validated in toxicology studies conducted in cynomolgus monkeys. Compared to Hu5F9-G4, Ligufalimab caused a significantly milder and more transient reduction in hemoglobin and hematocrit levels, with a much faster recovery to baseline.[4] This NHP data provided strong preclinical evidence that the engineered safety features of Ligufalimab would translate to a superior safety profile in humans.

Developer Profile and Strategic Context

The development and strategic positioning of Ligufalimab are intrinsically linked to the capabilities and vision of its developer, Akeso Inc. This section analyzes the company and the broader strategic context in which Ligufalimab is being advanced.

Akeso Inc.: An Emerging Innovator in Oncology

Akeso Inc. (HKEX: 9926.HK), founded in 2012, is a commercial-stage biopharmaceutical company headquartered in China with a rapidly expanding global presence.[3] The company has established fully integrated capabilities spanning the entire pharmaceutical value chain, from discovery research and clinical development to GMP-compliant manufacturing and commercialization.[3]

At the core of Akeso's innovation are its proprietary technology platforms. The ACE Platform is an end-to-end drug development system, while the Tetrabody technology is a specialized platform for the creation of novel bispecific antibodies.[3] These platforms have enabled Akeso to build a large and diversified pipeline of over 50 assets targeting cancer, autoimmune diseases, inflammation, and metabolic disorders.[3] As of late 2024, the company had over 19 candidates in clinical development and had successfully brought multiple innovative drugs to market in China, including Cadonilimab (PD-1/CTLA-4 bispecific) and Ivonescimab (PD-1/VEGF bispecific).[3]

Strategic Portfolio Synergy: The "Proprietary Combination" Moat

Akeso's clinical development strategy for Ligufalimab is distinguished by its deliberate focus on creating proprietary combination regimens. Rather than primarily pairing Ligufalimab with established, third-party standards of care like pembrolizumab or nivolumab, Akeso is prioritizing combinations with its own internally developed, high-value assets.[7] This approach creates a powerful synergy that extends beyond biology to establish a significant commercial advantage.

The two key combination partners for Ligufalimab from Akeso's portfolio are:

1. Ivonescimab (AK112/SMT112): A first-in-class bispecific antibody targeting both PD-1 and VEGF. The scientific rationale for this combination is compelling: it simultaneously targets three distinct and critical pathways in tumor biology. Ligufalimab activates the innate immune system (via CD47 blockade), while Ivonescimab blocks an adaptive immune checkpoint (PD-1) and inhibits tumor angiogenesis and vascularization (VEGF).[9] This multi-pronged attack has the potential to overcome tumor resistance and generate deep, durable responses.
2. Cadonilimab (AK104): The world's first approved PD-1/CTLA-4 bispecific antibody.[27] Combining Ligufalimab with Cadonilimab pairs a potent innate immune checkpoint inhibitor with a dual adaptive immune checkpoint inhibitor, aiming to achieve comprehensive activation of the anti-tumor immune response.

This strategy of building proprietary combinations creates a formidable competitive "moat." While a competitor might develop a single effective drug, Akeso is developing entire treatment regimens that it wholly owns. If these combinations prove superior to the existing standard of care—a hypothesis being directly tested in the Phase 3 HNSCC trial comparing Ligufalimab plus Ivonescimab against pembrolizumab monotherapy—Akeso will control the new standard.[8] This allows the company to capture the full commercial value of the regimen, a stark contrast to the typical scenario where a new drug's value is shared with the owner of the established drug it is combined with. This sophisticated, long-term strategy differentiates Akeso from many of its peers and underscores its ambition to become a global leader in oncology. Akeso's global aspirations are further supported by its strategic partnership with Summit Therapeutics, which holds the rights to develop and commercialize Ivonescimab in major ex-China markets, including the United States, Canada, Europe, and Japan, providing a clear pathway for the global commercialization of these proprietary combination therapies.[8]

Comprehensive Clinical Development Program

Ligufalimab is being evaluated in a broad and ambitious clinical development program that spans multiple tumor types and stages of development, from early-phase dose-escalation studies to global, registrational Phase 3 trials. The program is heavily focused on combination therapies, leveraging Akeso's synergistic portfolio strategy.

The following table provides a comprehensive overview of the publicly disclosed clinical trials involving Ligufalimab. This master list serves as a central reference for understanding the scope, priorities, and status of the entire development program.

NCT Number	Phase	Status	Indication(s)	Combination Agent(s)	Sponsor(s)
NCT06601335	3	Recruiting	Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	Ivonescimab	Akeso
NCT06196203	2	Recruiting	Myelodysplastic Syndromes (MDS)	Azacitidine	Akeso
NCT06789848	2	Recruiting	Advanced Liver Cancers (HCC, Bile Duct Cancer)	Cadonilimab	University of Texas Southwestern Medical Center
NCT05960955	2	Recruiting	Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	Cadonilimab, Chemotherapy	Akeso
NCT05382442	2	Recruiting	Metastatic Colorectal Cancer	Chemotherapy, +/- Ivonescimab	Akeso
NCT06508606	2	Not Yet Recruiting	Recurrent/Metastatic HNSCC	Anti-EGFR therapy	West China Hospital
NCT04900350	1 / 2	Active, Not Recruiting	Myelodysplastic Syndromes (MDS)	Azacitidine	Akeso
NCT06387420	1	Not Yet Recruiting	Acute Myeloid Leukemia (AML)	Azacitidine, Venetoclax	Akeso
NCT06642792	1	Recruiting	Classical Hodgkin's Lymphoma	+/- AK129 (anti-LAG-3/PD-1)	Akeso
NCT05214482	1	Active, Not Recruiting	Advanced Malignant Neoplasm	+/- Ivonescimab	Akeso
NCT04349969	1	Completed	Cancer	Monotherapy or + Cadonilimab	Akeso
NCT04728334	1	Completed	Cancer	Monotherapy	Akeso

Hematologic Malignancies

Akeso has identified hematologic malignancies as a core area of focus for Ligufalimab, targeting diseases where CD47 is highly expressed and where there is a significant unmet need for safer, more effective therapies.

Myelodysplastic Syndromes (MDS): The program in higher-risk MDS (HR-MDS) is one of the most advanced for Ligufalimab. The standard of care for HR-MDS patients, who are often older and have comorbidities, typically involves treatment with hypomethylating agents such as azacitidine, with allogeneic stem cell transplant being the only potentially curative option.[35] However, response rates to azacitidine are modest, and many patients are ineligible for transplant, creating a significant need for new therapies.[3] Akeso is evaluating Ligufalimab in combination with azacitidine in a global Phase 2 trial (NCT06196203) and a preceding Phase 1/2 study (NCT04900350).[10] The initiation of enrollment in the United States for the Phase 2 trial underscores Akeso's global ambitions and its strategy to pursue simultaneous development for both Chinese and Western markets, aiming for "global approval and commercialization".[3]

Acute Myeloid Leukemia (AML): The development strategy in AML targets a particularly vulnerable patient population: those who are newly diagnosed but are ineligible for intensive induction chemotherapy due to age or comorbidities.[3] For these patients, the prognosis is poor, and less intensive options are needed.[39] Akeso is planning a Phase 1 trial (NCT06387420) to evaluate a triplet combination of Ligufalimab with azacitidine and the BCL-2 inhibitor venetoclax.[16] This regimen aims to build upon the emerging standard of care (azacitidine + venetoclax) by adding an innate immune checkpoint inhibitor to potentially deepen responses and improve outcomes.[41]

Lymphomas: The clinical program also includes an early-stage exploration in relapsed or refractory Classical Hodgkin's Lymphoma (NCT06642792).[16] This Phase 1 trial will evaluate Ligufalimab in combination with another of Akeso's bispecific antibodies, AK129, which targets LAG-3 and PD-1.

Solid Tumors

Ligufalimab is being aggressively developed across a broad range of solid tumors, where the strategy is heavily reliant on proprietary combinations with Ivonescimab and Cadonilimab.

Head and Neck Squamous Cell Carcinoma (HNSCC): The HNSCC program represents a flagship initiative for Akeso and is the most advanced solid tumor indication for Ligufalimab. The company has initiated a pivotal, randomized Phase 3 trial (NCT06601335) for the first-line treatment of recurrent or metastatic HNSCC.[8] This study is notable for several reasons: it is the first Phase 3 trial worldwide for a CD47 antibody in solid tumors, and its design is exceptionally ambitious.[8] The trial directly compares the proprietary combination of Ligufalimab plus Ivonescimab against the established PD-1 inhibitor standard of care, pembrolizumab.[7] This high-risk, high-reward approach is not aimed at incremental improvement but at establishing an entirely new, Akeso-owned standard of care for this patient population, who currently have a median overall survival of under one year despite immunotherapy.[8]

Gastrointestinal and Hepatobiliary Cancers: This is another major area of focus, with multiple Phase 2 trials underway. In advanced liver cancers, including hepatocellular carcinoma (HCC) and biliary tract cancers, a trial sponsored by the University of Texas Southwestern Medical Center is evaluating Ligufalimab in combination with Cadonilimab (NCT06789848).[16] In metastatic colorectal cancer, a Phase 2 trial (NCT05382442) is exploring Ligufalimab in combination with chemotherapy and Ivonescimab.[16] A similar Phase 2 study (NCT05960955) is investigating Ligufalimab with Cadonilimab and chemotherapy in gastric and gastroesophageal junction adenocarcinoma.[16] This cluster of trials demonstrates a concerted effort to establish Ligufalimab as a key combination agent in high-incidence GI tumors.

Other Solid Tumors: The solid tumor program was initiated with broader, signal-seeking Phase 1 studies in patients with various advanced cancers (NCT04349969, NCT04728334, NCT05214482).[48] These trials served to establish the safety, tolerability, and recommended dose of Ligufalimab, both as a monotherapy and in combination with agents like Cadonilimab and Ivonescimab, paving the way for the more focused, later-stage trials. The company also received approval from China's NMPA to initiate a Phase 2 trial in triple-negative breast cancer in combination with Ivonescimab and chemotherapy.[9]

Analysis of Clinical Efficacy and Safety

While much of the clinical development program for Ligufalimab is ongoing, emerging data presented at major medical conferences have provided an early look at its efficacy and have largely validated the promising preclinical safety profile in human subjects.

Emerging Efficacy Data

The most mature clinical data for Ligufalimab come from its studies in hematologic malignancies, which were presented at the 65th American Society of Hematology (ASH) Annual Meeting in 2023.[3]

Hematologic Malignancies (ASH 2023 Data):

• Higher-Risk Myelodysplastic Syndromes (HR-MDS): In a Phase 1b study of Ligufalimab combined with azacitidine for newly diagnosed HR-MDS, the results were highly encouraging.[12] Among 27 evaluable patients, the overall response rate (ORR) was 85.2%, and the complete remission (CR) rate was 48.1%. The depth of response appeared to increase with continued treatment, as the CR rate rose to 68.4% in patients who received six or more cycles of therapy. Responses were also rapid, with a median time to response of just 0.97 months.[11] Critically, the combination demonstrated a significant clinical benefit in alleviating anemia, a major cause of morbidity in MDS. Of 13 patients who were dependent on red blood cell transfusions at baseline, 61.5% became transfusion-independent during the study.[11]
• Acute Myeloid Leukemia (AML): In treatment-naïve AML patients who were unfit for intensive chemotherapy, the combination of Ligufalimab and azacitidine also showed promising activity. Among 20 evaluable patients, the composite complete remission (CCR) rate was 55%, with 50% of patients achieving a CR.[12]

Solid Tumors (ESMO 2024 Data):

• Head and Neck Squamous Cell Carcinoma (HNSCC): Preliminary data presented at the European Society for Medical Oncology (ESMO) Congress for the combination of Ligufalimab and Ivonescimab in HNSCC showed significant tumor reduction and survival benefits. The efficacy signals were reported to exceed those seen in previous studies of PD-1 inhibitors alone, providing the rationale for advancing the combination into the pivotal Phase 3 trial.[8]
• Metastatic Colorectal Cancer (mCRC): At the same meeting, initial results from the combination of Ligufalimab, Ivonescimab, and FOLFOXIRI chemotherapy in first-line mCRC also demonstrated promising efficacy and a tolerable safety profile.[7]

Clinical Safety and Tolerability Profile

The clinical safety data generated to date represent the most critical validation of Ligufalimab's core value proposition. The evidence strongly supports the preclinical hypothesis that its unique design translates into a superior safety profile compared to first-generation CD47 inhibitors.

• Low Incidence of Anemia: The data from the HR-MDS study are particularly compelling. In a safety population of 86 patients, treatment-related anemia—the primary adverse event of concern for the CD47 inhibitor class—was reported in only 29.1% of patients.[11] This relatively low incidence in a hematologically vulnerable population is a key point of differentiation.
• No Priming Dose Required: Consistent with its engineered properties, Ligufalimab is administered at its full therapeutic dose from the outset, without the need for a lower "priming dose".[4] This simplifies the treatment regimen, reduces the risk of sub-therapeutic exposure, and underscores its favorable hematologic safety.
• Overall Tolerability: Across multiple Phase 1 and Phase 2 studies, Ligufalimab has been reported to be safe and well-tolerated, both as a monotherapy and in various combination regimens.[3] No dose-limiting toxicities (DLTs) have been observed, and there have been no reports of severe treatment-related adverse events or infusion-related reactions.[3] This clean safety profile is crucial for its role as a combination partner, as it is less likely to exacerbate the toxicities of other anti-cancer agents.

Competitive Landscape and Market Positioning

Ligufalimab is entering a dynamic and competitive therapeutic space. Its potential for success depends not only on its own merits but also on how it is positioned relative to other agents targeting the CD47-SIRPα pathway.

The CD47 Inhibitor Class: Promise and Peril

The CD47-SIRPα axis has emerged as one of the most promising novel targets in immuno-oncology, offering a mechanism to engage the innate immune system to fight cancer.[52] Its broad expression across many tumor types suggests wide applicability for both hematologic and solid malignancies.[20] However, the development of this class has been fraught with challenges, primarily the on-target hematotoxicity that has led to clinical holds and program terminations for some first-generation agents.[5] The central challenge for any new entrant is to demonstrate a compelling therapeutic window, balancing potent anti-tumor efficacy with a manageable safety profile.[53]

Competitor Analysis

The field of CD47-targeted therapies includes several key players at various stages of development. Ligufalimab's position can be best understood through a direct comparison with these competitors. The first-mover in this space, magrolimab, clinically de-risked the CD47 target, demonstrating its therapeutic potential. However, it also revealed the significant safety hurdles associated with the class. This created a clear opportunity for a "fast follower" to enter the market with an improved, safer alternative. Ligufalimab, with its engineered safety profile, was designed to fill this exact role. By learning from the challenges of its predecessors and developing a solution to the class's primary weakness, Akeso has positioned Ligufalimab not as a simple follower, but as a contender for the best-in-class designation. The clinical setbacks faced by some competitors do not necessarily weaken the case for the CD47 class as a whole; instead, they strengthen the competitive position of a differentiated and safer agent like Ligufalimab.

Attribute	Ligufalimab (AK 117)	Magrolimab (Hu5F9-G4)	Lemzoparlimab (TJC4)	Evorpacept (ALX148)	TTI-622
Developer	Akeso Inc.	Gilead (via Forty Seven)	I-Mab Biopharma	ALX Oncology	Pfizer (via Trillium)
Molecule Type	Humanized IgG4 mAb	Humanized IgG4 mAb	Human IgG4 mAb	SIRPα-Fc Fusion Protein	SIRPα-IgG4 Fc Fusion Protein
Key Differentiator	Unique binding epitope; no hemagglutination	First-in-class mAb	RBC-sparing property; unique epitope	High affinity; inactive Fc domain	Does not bind RBCs
Hematologic Safety	Low incidence of anemia; no priming dose needed	Anemia is a key AE; requires priming dose	Designed to minimize RBC binding	Inactive Fc avoids indiscriminate "eat me" signal	Does not bind RBCs
Lead Indications	HR-MDS, HNSCC, AML	HR-MDS, AML	MDS, AML, Solid Tumors	HNSCC, Gastric Cancer	Lymphoma, Multiple Myeloma
Highest Phase	Phase 3	Phase 3 (some studies halted)	Phase 3	Phase 2/3	Phase 1b

Market Positioning and Strategic Advantage

Based on the available data, Ligufalimab is strongly positioned as a second-generation, potentially best-in-class CD47 inhibitor. Its strategic advantages are twofold:

1. Superior Safety Profile: The most significant differentiator is its demonstrated clinical safety, particularly the low incidence of anemia and the lack of a need for a priming dose. This could lead to better patient tolerability, more consistent therapeutic exposure, and broader applicability, especially in combination regimens where minimizing cumulative toxicity is critical.
2. Synergistic Portfolio Strategy: Akeso's strategy of creating proprietary combinations with its novel bispecific antibodies (Ivonescimab and Cadonilimab) provides a unique and durable competitive advantage. This approach has the potential to establish new, wholly-owned standards of care that competitors cannot easily replicate.

Regulatory Status

As an investigational drug, Ligufalimab has not yet received marketing approval from any major regulatory agency. Its status with key global health authorities is summarized below.

U.S. Food and Drug Administration (FDA)

A review of publicly available FDA databases confirms that Ligufalimab has not received marketing approval, accelerated approval, or any special designations such as Breakthrough Therapy or Orphan Drug Designation in the United States.[57] Akeso has received clearance from the FDA for its Investigational New Drug (IND) application to conduct the global Phase 2 study of Ligufalimab in combination with azacitidine for the treatment of HR-MDS, which is a standard procedural step for conducting clinical trials in the U.S..[11]

European Medicines Agency (EMA)

There is no evidence to suggest that Ligufalimab has received a marketing authorisation or any special designations, such as the PRIME (Priority Medicines) scheme, from the European Medicines Agency.[16]

China National Medical Products Administration (NMPA)

Ligufalimab is actively progressing through the clinical development pathway in China. The NMPA has granted Akeso approval to initiate multiple clinical trials, including a Phase 2 trial for triple-negative breast cancer and Phase 1/2 trials for MDS.[9]

Future Outlook and Concluding Assessment

This final section synthesizes the preceding analysis to offer a forward-looking perspective on Ligufalimab's trajectory, opportunities, risks, and overall potential to impact the treatment of cancer.

Projected Development and Commercial Trajectory

The development path for Ligufalimab is approaching several critical inflection points. The most significant near-term catalysts will be the data readouts from its late-stage clinical trials. Positive results from the global Phase 2 trial in HR-MDS (NCT06196203) and, most importantly, the pivotal Phase 3 trial in HNSCC (NCT06601335) could form the basis for regulatory submissions in China, the United States, and other major markets. Success in the HNSCC trial, in particular, would be a transformative event, potentially establishing a new global standard of care. Looking forward, Akeso is expected to continue its expansion into other solid tumors, leveraging its proprietary combination strategy with Ivonescimab and Cadonilimab to address high-unmet-need indications in gastrointestinal and other cancers.

Unmet Needs and Opportunities

Ligufalimab is well-positioned to address clear and significant unmet medical needs. In hematologic malignancies, it offers the potential for a safer and more effective treatment for older or frail patients with HR-MDS and AML who cannot tolerate intensive chemotherapy. The ability to improve response rates while reducing transfusion dependence would be a major clinical advance. In solid tumors, the primary opportunity lies in its potential to improve upon the efficacy of current immunotherapy standards of care, as is being tested in HNSCC. Its superior safety profile creates a substantial opportunity for it to become the CD47 inhibitor of choice for a wide range of novel combination therapies, both within Akeso's portfolio and with potential external partners.

Potential Risks and Mitigation Strategies

Despite its promise, the Ligufalimab program faces several risks:

• Clinical Risk: The bar for success in the Phase 3 HNSCC trial is exceptionally high, as it aims to demonstrate superiority over an established and effective standard of care (pembrolizumab). Failure to meet this high bar would be a significant setback for the solid tumor program.
• Competitive Risk: The CD47 inhibitor space remains competitive, with several companies developing next-generation agents with their own RBC-sparing technologies. A competitor could emerge with a superior efficacy profile or a different safety advantage.
• Execution Risk: Akeso is managing a broad, complex, and global clinical program. Ensuring timely enrollment, consistent execution, and data integrity across multiple international trials is a major operational challenge. The company's partnership with Summit Therapeutics for Ivonescimab helps to mitigate the commercialization and execution risk in key markets outside of China.

Concluding Assessment

Ligufalimab is a highly promising and intelligently designed second-generation CD47 inhibitor. Its key innovation—a differentiated safety profile that effectively addresses the primary liability of its predecessors—is not an incremental improvement but a fundamental advance for the therapeutic class. This safety advantage, when combined with Akeso's sophisticated and synergistic proprietary combination strategy, provides Ligufalimab with a credible and compelling path toward becoming a cornerstone of immuno-oncology therapy. It has the potential to deliver significant clinical benefit in both hematologic malignancies and solid tumors. Its ultimate success will be contingent on the execution of its ambitious late-stage clinical trials and on demonstrating that its clear safety advantages translate into a superior net clinical benefit for patients with cancer.

Works cited

1. Ligufalimab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 18, 2025, https://go.drugbank.com/drugs/DB17542
2. Ligufalimab (AK 117) | CAS 2428381-55-7 | AbMole BioScience, accessed August 18, 2025, https://www.abmole.com/products/ligufalimab.html
3. First US Patient Enrolled in Phase 2 Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome - Patsnap Synapse, accessed August 18, 2025, https://synapse.patsnap.com/article/first-us-patient-enrolled-in-phase-2-therapy-of-akesos-ligufalimab-with-azacitidine-for-myelodysplastic-syndrome
4. JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) mechanism shows promising antitumor efficacy and favorable safety profile - BioSpace, accessed August 18, 2025, https://www.biospace.com/jitc-publication-of-akeso-s-ligufalimab-cd47-monoclonal-antibody-mechanism-shows-promising-antitumor-efficacy-and-favorable-safety-profile
5. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9717234/
6. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity, accessed August 18, 2025, https://jitc.bmj.com/content/10/11/e005517
7. Akeso's CD47 heads for phase 3 | ApexOnco - Oncology Pipeline, accessed August 18, 2025, https://www.oncologypipeline.com/apexonco/akesos-cd47-heads-phase-3
8. Akeso Enrolls First Patient in Phase 3 Trial of Ivonescimab and Ligufalimab for HNSCC, Compared to Pembrolizumab - Patsnap Synapse, accessed August 18, 2025, https://synapse.patsnap.com/article/akeso-enrolls-first-patient-in-phase-3-trial-of-ivonescimab-and-ligufalimab-for-hnscc-compared-to-pembrolizumab
9. Akeso's Ligufalimab And Ivonescimab Obtained Approval To Initiate A Phase II Trial, accessed August 18, 2025, https://www.biospace.com/akeso-s-ligufalimab-and-ivonescimab-obtained-approval-to-initiate-a-phase-ii-trial
10. Myelodysplastic Disorders Active Not Recruiting Phase 1 / 2 Trials for Ligufalimab (DB17542) - DrugBank, accessed August 18, 2025, https://go.drugbank.com/indications/DBCOND0030055/clinical_trials/DB17542?phase=1%2C2&status=active_not_recruiting
11. Akeso announces results from CD47 antibody ligufalimab in combination with azacitidine for higher-risk myelodysplastic syndrome - Pharmabiz.com, accessed August 18, 2025, https://www.pharmabiz.com/PrintArticle.aspx?aid=165272&sid=2
12. Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023 - PR Newswire, accessed August 18, 2025, https://www.prnewswire.com/news-releases/akeso-published-results-from-cd47-antibody-ligufalimab-in-combination-with-azacitidine-for-newly-diagnosed-higher-risk-myelodysplastic-syndrome-and-treatment-naive-acute-myeloid-leukemia-at-ash-2023-302016538.html
13. Ligufalimab Biosimilar – Anti-CD47 mAb – Research Grade - ProteoGenix, accessed August 18, 2025, https://us.proteogenix.science/product/ligufalimab-biosimilar-anti-cd47-mab-research-grade/
14. 2428381-55-7 | Ligufalimab - Aaronchem, accessed August 18, 2025, https://www.aaronchem.com/2428381-55-7
15. Ligufalimab (Anti-CD47) CD markers antibody | Read Reviews & Product Use Citations - Selleck Chemicals, accessed August 18, 2025, https://www.selleckchem.com/products/ligufalimab-anti-cd47.html
16. Ligufalimab | MedPath, accessed August 18, 2025, https://trial.medpath.com/drug/bc52266d1e900dfb/ligufalimab
17. Ligufalimab (AK 117) | Anti CD47 Monoclonal Antibody | MedChemExpress, accessed August 18, 2025, https://www.medchemexpress.com/ligufalimab.html
18. Definition of ligufalimab - NCI Drug Dictionary - NCI, accessed August 18, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ligufalimab
19. Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives - PubMed Central, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11261161/
20. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity - ResearchGate, accessed August 18, 2025, https://www.researchgate.net/publication/365882494_Ligufalimab_a_novel_anti-CD47_antibody_with_no_hemagglutination_demonstrates_both_monotherapy_and_combo_antitumor_activity
21. Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7687918/
22. ontosight.ai, accessed August 18, 2025, https://ontosight.ai/glossary/term/ligufalimab-cancer-treatment-overview--67a101fe6c3593987a520c3e#:~:text=The%20primary%20mechanism%20of%20action,evade%20immune%20detection%20and%20destruction.
23. Ligufalimab Cancer Treatment Overview - Ontosight, accessed August 18, 2025, https://ontosight.ai/glossary/term/ligufalimab-cancer-treatment-overview--67a101fe6c3593987a520c3e
24. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity - The Journal for ImmunoTherapy of Cancer, accessed August 18, 2025, https://jitc.bmj.com/content/jitc/10/11/e005517.full.pdf
25. Magrolimab in Combination With Azacitidine in Patients With Higher ..., accessed August 18, 2025, https://ascopubs.org/doi/10.1200/JCO.22.01794
26. JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) mechanism shows promising antitumor efficacy and favorable safety profile - PR Newswire, accessed August 18, 2025, https://www.prnewswire.com/news-releases/jitc-publication-of-akesos-ligufalimabcd47-monoclonal-antibody-mechanism-shows-promising-antitumor-efficacy-and-favorable-safety-profile-301699983.html
27. First Patient Enrolled in the US Phase 2 Combination Therapy of ..., accessed August 18, 2025, https://www.pharmafocusasia.com/pressreleases/first-patient-enrolled-in-the-us-phase-combination-therapy
28. Akeso Biopharma | The Pharmaletter, accessed August 18, 2025, https://www.thepharmaletter.com/akeso-biopharma
29. First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome - PR Newswire, accessed August 18, 2025, https://www.prnewswire.com/news-releases/first-patient-enrolled-in-the-us-phase-2-combination-therapy-of-akesos-ligufalimab-with-azacitidine-for-myelodysplastic-syndrome-302215078.html
30. Akeso Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed August 18, 2025, https://synapse.patsnap.com/organization/f8909923771a8fb556c2708a8762c0a8
31. Akeso, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed August 18, 2025, https://synapse.patsnap.com/organization/7a1651c53842307381146217c3025e2c
32. Pipeline - Summit Therapeutics, accessed August 18, 2025, https://www.smmttx.com/pipeline/
33. Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer - BioSpace, accessed August 18, 2025, https://www.biospace.com/press-releases/akeso-announces-first-patient-enrollment-in-phase-iii-trial-of-ivonescimab-for-pancreatic-cancer
34. Strategic Partnership with Akeso - Summit Therapeutics, accessed August 18, 2025, https://www.smmttx.com/ivonescimab-smt112/strategic-partnership-with-akeso/
35. MDS Treatment Options | Myelodysplastic Syndromes - Rogel Cancer Center, accessed August 18, 2025, https://www.rogelcancercenter.org/myelodysplastic-syndromes/mds-treatment-options
36. How We Treat Myelodysplastic Syndromes (MDS) | Dana-Farber ..., accessed August 18, 2025, https://www.dana-farber.org/cancer-care/types/myelodysplastic-syndromes/treatment
37. Current Standard of Care in Patients with Myelodysplastic Syndromes and Future Perspectives, accessed August 18, 2025, https://onco-hema.healthbooktimes.org/article/25627-current-standard-of-care-in-patients-with-myelodysplastic-syndromes-and-future-perspectives
38. First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome - BioSpace, accessed August 18, 2025, https://www.biospace.com/first-patient-enrolled-in-the-us-phase-2-combination-therapy-of-akesos-ligufalimab-with-azacitidine-for-myelodysplastic-syndrome
39. Treating Acute Myeloid Leukemia (AML) - American Cancer Society, accessed August 18, 2025, https://www.cancer.org/cancer/types/acute-myeloid-leukemia/treating.html
40. Acute Myeloid Leukemia - StatPearls - NCBI Bookshelf, accessed August 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK507875/
41. Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version - National Cancer Institute, accessed August 18, 2025, https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
42. Typical Treatment of Acute Myeloid Leukemia (Except APL) | American Cancer Society, accessed August 18, 2025, https://www.cancer.org/cancer/types/acute-myeloid-leukemia/treating/typical-treatment-of-aml.html
43. Ligufalimab Recruiting Phase 1 Trials for Classical Hodgkin's Lymphoma Treatment, accessed August 18, 2025, https://go.drugbank.com/drugs/DB17542/clinical_trials?conditions=DBCOND0113588&phase=1&purpose=treatment&status=recruiting
44. Squamous cell carcinoma of head and neck: what internists should ..., accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7487309/
45. Ligufalimab Recruiting Phase 2 Trials for Bile Duct Cancer / Advanced Hepatocellular Carcinoma (HCC) Treatment - DrugBank, accessed August 18, 2025, https://go.drugbank.com/drugs/DB17542/clinical_trials?conditions=DBCOND0046987%2CDBCOND0032251&phase=2&purpose=treatment&status=recruiting
46. Study Details | Ligufalimab and Cadonilimab in Advanced Liver ..., accessed August 18, 2025, https://clinicaltrials.gov/study/NCT06789848
47. Ligufalimab Clinical Naked monospecific - YAbS database - The Antibody Society, accessed August 18, 2025, https://db.antibodysociety.org/db0/252/
48. Ligufalimab Completed Phase 1 Trials for Cancer Treatment | DrugBank Online, accessed August 18, 2025, https://go.drugbank.com/drugs/DB17542/clinical_trials?conditions=DBCOND0020966&phase=1&purpose=treatment&status=completed
49. Ligufalimab Active Not Recruiting Phase 1 Trials for Advanced Malignant Neoplasm Treatment | DrugBank Online, accessed August 18, 2025, https://go.drugbank.com/drugs/DB17542/clinical_trials?conditions=DBCOND0033490&phase=1&purpose=treatment&status=active_not_recruiting
50. ligufalimab (AK117) / Akesobio - LARVOL DELTA, accessed August 18, 2025, https://delta.larvol.com/Products/?ProductId=eb55a691-d3f2-4cca-8b3a-aab288e45dd9
51. Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study. | Request PDF - ResearchGate, accessed August 18, 2025, https://www.researchgate.net/publication/352089274_Safety_of_AK117_an_anti-CD47_monoclonal_antibody_in_patients_with_advanced_or_metastatic_solid_tumors_in_a_phase_I_study
52. Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data - Frontiers, accessed August 18, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1027235/full
53. CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs - BioSpace, accessed August 18, 2025, https://www.biospace.com/press-releases/cd47-inhibitor-drug-clinical-trials-market-outlook-to-2028-emerging-cd47-inhibitor-clinical-trials-showcase-potential-cancer-treatment-breakthroughs
54. CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer, accessed August 18, 2025, https://www.mdpi.com/2072-6694/15/21/5229
55. Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10767231/
56. Opportunities and challenges for anti-CD47 antibodies in hematological malignancies - Frontiers, accessed August 18, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1348852/full
57. Biosimilar Product Information - FDA, accessed August 18, 2025, https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
58. Oncology (Cancer)/Hematologic Malignancies Approval ... - FDA, accessed August 18, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
59. Search Orphan Drug Designations and Approvals - FDA, accessed August 18, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=915722
60. Medicines | European Medicines Agency (EMA), accessed August 18, 2025, https://www.ema.europa.eu/en/medicines
61. Ligufalimab - Akeso Biopharma - AdisInsight - Springer, accessed August 18, 2025, https://adisinsight.springer.com/drugs/800051520